Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $22

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $25 to $22.
byBenzinga Newsdesk
July 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $25 to $22.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0